A Phase I Clinical Study of Oral CP-4126 in Patients With Advanced Solid Tumour
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
At step 1, patients with advanced solid tumors will receive CP-4126 capsules following a dose
escalation schedule until the maximum tolerated dose is reached. At step 2, 20 patients will
be randomized. They will receive at days 1 and 8 in a double cross design either oral CP-4126
at the recommended dose or gemcitabine 1000mg/m2 intravenously. At both steps, the schedule
of treatment will be day 1, 8, 15 q4w until complete response or disease worsening/
progressing. All further treatment at step 2 will be oral CP-4126.